Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients
NCT03708861Phase 3Withdrawn
- Sponsor
- University of Turin
- Start
- Jan 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of maraviroc in human immunodeficiency virus infection (HIV), sponsored by University of Turin. Primary endpoint: Pharmacokinetic evaluation of maraviroc and atazanavir/ritonavir at 16 weeks. Planned start Jan 2016; status: withdrawn.
02
Drugs
maraviroc
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03708861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03708861.